PRPO Precipio Dashboard

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

Company profile

Ticker

PRPO

Exchange

NASDAQ

Website

www.precipiodx.com

CEO

Paul Kinnon

Incorporated

Delaware

Location

Nebraska

Fiscal year end

Dec 31

Sector

Manufacturing > Analytical Laboratory Instrument Manufacturing

Industry (SIC)

Laboratory Analytical Instruments

Agilent • Perkinelmer • Bio-Rad Laboratories • Avantor • Waters • Mettler-Toledo International • Illumina • Bruker • Coherent • Seer ...

Former names

TRANSGENOMIC INC

SEC CIK

0001043961

Corporate docs

Articles of Incorporation & Bylaws

IRS number

911789357

PRPO stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

12 Health Care Stocks Moving In Thursday's After-Market Session

1 Jul 21

Gainers

Precipio Terminates Equity Line With Lincoln Park Capital

15 Jun 21

Specialty diagnostics Company Precipio, Inc. (NASDAQ:PRPO), announces that as part of management's review of its current financing arrangements, it has terminated the equity line financing structure it had

62 Biggest Movers From Yesterday

10 Jun 21

Gainers

12 Health Care Stocks Moving In Wednesday's Intraday Session

9 Jun 21

48 Stocks Moving In Wednesday's Mid-Day Session

9 Jun 21

Press releases

Pro users get this 30m faster

Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M

28 Jul 21

NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics Company Precipio, Inc. (NASDAQ:PRPO), announces preliminary unaudited revenues for Q2-2021 demonstrating continued substantial YoY and quarterly

Thinking about buying stock in Allied Esports Entertainment, Frontline, Naked Brand, Chevron, or Precipio?

2 Jul 21

NEW YORK, July 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AESE, FRO, NAKD, CVX, and PRPO.

Precipio Terminates its Equity Line

15 Jun 21

NEW HAVEN, Conn., June 15, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics Company Precipio, Inc. (NASDAQ:PRPO), announces that as part of management's review of its current financing arrangements, it has terminated the

Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool

8 Jun 21

Precipio, Inc. to Host Earnings Call

20 May 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

14 May 21

30 Jul 21

31 Dec 21

Financial summary

Financial statements Chart PRPO financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Precipio earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.29M	2.29M	2.29M	2.29M	2.29M	2.29M
Cash burn (monthly)	123.33K	(positive/no burn)	712.33K	828.33K	433.33K	595.42K
Cash used (since last report)	493.4K	n/a	2.85M	3.31M	1.73M	2.38M
Cash remaining	1.79M	n/a	-563.71K	-1.03M	552.44K	-95.98K
Runway (months of cash)	14.5	n/a	-0.8	-1.2	1.3	-0.2

Beta Read what these cash burn values mean

Recent insider trades

PRPO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Jun 21	Sabet Ahmed Zaki	Common Stock	Buy	Aquire P	No	No	3.369	151	508.72	4,879
1 Jun 21	Danieli Ilan	Common Stock	Buy	Aquire P	No	No	3.3713	755	2.55K	22,217
1 Mar 21	Danieli Ilan	Common Stock	Buy	Aquire P	No	No	2.46	1,025	2.52K	21,462
1 Mar 21	Andrews Ronald Asbury	Employee Stock Option Common Stock	Grant	Aquire A	No	No	2.6	5,171	13.44K	5.171
1 Mar 21	Andrews Ronald Asbury	Employee Stock Option Common Stock	Grant	Aquire A	No	No	2.6	2,069	5.38K	2,069

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

PRPO institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Quest Diagnostics • Neogenomics • Cardiff Oncology • Guardant Health

Risks

We face risks related to health pandemics and other widespread outbreaks of contagious disease, including the novel coronavirus, COVID-19, which could significantly disrupt our operations and impact our financial results.

Management Discussion

Net Change in Cash. Cash increased by $1.8 million and $0.5 million during the years ended December 31, 2020 and 2019, respectively.
Cash Flows Used in Operating Activities. The cash flows used in operating activities of $7.4 million during the year ended December 31, 2020 included a net loss of $10.6 million, an increase in accounts receivable of $1.6 million, an increase in inventories and other assets of $0.2 million and a decrease in accounts payable and operating lease liabilities of $0.5 million. These were partially offset by an increase in accrued expenses and other liabilities of $0.7 million and non-cash adjustments of $4.8 million. The non-cash adjustments included $1.3 million for the change in provision for losses on doubtful accounts. We routinely provide a reserve for doubtful accounts as a result of having limited in-network payer contracts. Non-cash adjustments also included $1.2 million for loss on extinguishment of convertible notes, which resulted from a March 2020 amendment to certain Bridge Notes whereby, among other things, the floor price at which conversions may occur was amended from $2.25 to $0.40. See Note 6 – Convertible Notes for further discussion. The other non-cash adjustments to net loss of approximately $2.3 million include, among other things, depreciation and amortization, warrant revaluations and stock based compensation. The cash flows used in operating activities in the year ended December 31, 2019 included the net loss of $13.2 million, an increase in accounts receivable of $0.8 million, a decrease in accounts payable of $1.9 million and a decrease in operating lease liabilities of $0.2 million. These were partially offset by a decrease in other assets of $0.4 million and non-cash adjustments of $6.6 million.
Cash Flows Used In Investing Activities. Cash flows used in investing activities were $0.1 million for the years ended December 31, 2020 and 2019, respectively, resulting from purchases of property and equipment partially offset by proceeds from sales of fixed assets.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: acute, agent, Amazon, AML, ATM, biotech, California, consent, consulting, counsel, derecognition, derecognized, float, forgiven, headcount, hematologic, indemnification, Instruction, Korean, large, leukemia, lower, manufactured, met, minute, MPN, myeloid, myeloproliferative, National, neoplasm, NPI, pathologist, pathology, pharma, practitioner, proprietary, rapid, reclassified, routinely, settle, settled, size, South, staffed, staffing, statute, sublease, transitioned, transitioning, type, unissued, upfront, USA, variety, website, writing, yield

Removed: adhere, aggregated, alleging, alternative, analyst, approach, approval, approving, arrangement, assign, begun, beneficially, bid, bifurcated, Bloomberg, breach, bringing, Campbell, canceled, Carlo, center, cloud, commencing, committed, composite, compute, computed, computing, consecutive, contemplated, continued, corporate, Corporation, Court, coverage, Crede, cumulative, daily, deal, delisted, delisting, deny, depending, derivative, deter, directing, disclose, discount, dissolution, distributed, District, earlier, embedded, enable, equal, equitably, escrow, event, exceed, exclusively, exempt, existed, governance, Group, high, holder, host, hosting, house, implementation, incomplete, independent, indeterminate, individually, insufficient, involuntary, issuing, Jesse, lawsuit, lesser, letter, Leviston, licensed, limitation, liquidated, liquidation, listed, longer, lowest, maintaining, maximum, methodology, misleading, Monte, negatively, notifying, occurrence, occurring, October, omission, owing, pari, participated, passu, penalty, penny, preliminarily, prohibition, proxy, ratably, reassessed, recapitalization, redeem, redemption, reduced, referred, refusal, regain, regular, release, released, remeasured, removal, removed, reorganization, repayment, representing, requiring, residing, restatement, reversal, reverse, satisfy, secondary, Secretary, selected, shareholder, similarly, situated, software, split, stipulation, stockholder, stringent, suit, superior, thereon, thereunder, timing, unamortized, unchanged, unpaid, upside, utilize, voluntary, VWAP, whichever, wrote

From filing 10-Q 2021 Q1